珀萊雅(603605.SH):前三季度彩棠、悦芙媞、OR都保持了50%以上的高增長
格隆匯10月26日丨珀萊雅(603605.SH)2023三季報業績説明會會議紀要顯示,今年前三季度,公司旗下的彩棠、悦芙媞、OR都保持了50%以上的高增長:
(1)彩棠:品牌對產品的打磨要求比較高,後續將持續完善底粧類目,加快粉底液、氣墊、粉餅、粉霜等底粧產品的升級和推新,看好彩棠未來發展空間。
(2)悦芙媞:優化品類結構,對品類進一步拓展和完善,在原料、配方等方面持續升級,提升產品力、科技力。
(3)OR(Off&Relax):進一步整合研發和供應鏈資源,開發品牌獨有原料,升級產品配方,優化品牌定位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.